| AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease ME Rinella, BA Neuschwander-Tetri, MS Siddiqui, MF Abdelmalek, ... Hepatology 77 (5), 1797-1835, 2023 | 660 | 2023 |
| Vibration-controlled transient elastography to assess fibrosis and steatosis in patients with nonalcoholic fatty liver disease MS Siddiqui, R Vuppalanchi, ML Van Natta, E Hallinan, KV Kowdley, ... Clinical Gastroenterology and Hepatology 17 (1), 156-163. e2, 2019 | 417 | 2019 |
| Obesity paradox in cardiovascular disease: where do we stand? S Carbone, JM Canada, HE Billingsley, MS Siddiqui, A Elagizi, CJ Lavie Vascular health and risk management, 89-100, 2019 | 415 | 2019 |
| The presence and severity of nonalcoholic steatohepatitis is associated with specific changes in circulating bile acids P Puri, K Daita, A Joyce, F Mirshahi, PK Santhekadur, S Cazanave, ... Hepatology 67 (2), 534-548, 2018 | 369 | 2018 |
| Randomised clinical trial: Lactobacillus GG modulates gut microbiome, metabolome and endotoxemia in patients with cirrhosis JS Bajaj, DM Heuman, PB Hylemon, AJ Sanyal, P Puri, RK Sterling, ... Alimentary pharmacology & therapeutics 39 (10), 1113-1125, 2014 | 320 | 2014 |
| The Stroop smartphone application is a short and valid method to screen for minimal hepatic encephalopathy JS Bajaj, LR Thacker, DM Heuman, M Fuchs, RK Sterling, AJ Sanyal, ... Hepatology 58 (3), 1122-1132, 2013 | 278 | 2013 |
| Fecal microbial transplant capsules are safe in hepatic encephalopathy: a phase 1, randomized, placebo‐controlled trial JS Bajaj, NH Salzman, C Acharya, RK Sterling, MB White, EA Gavis, ... Hepatology 70 (5), 1690-1703, 2019 | 255 | 2019 |
| Performance characteristics of vibration‐controlled transient elastography for evaluation of nonalcoholic fatty liver disease R Vuppalanchi, MS Siddiqui, ML Van Natta, E Hallinan, D Brandman, ... Hepatology 67 (1), 134-144, 2018 | 252 | 2018 |
| Severity of nonalcoholic fatty liver disease and progression to cirrhosis are associated with atherogenic lipoprotein profile MS Siddiqui, M Fuchs, MO Idowu, VA Luketic, S Boyett, C Sargeant, ... Clinical Gastroenterology and Hepatology 13 (5), 1000-1008. e3, 2015 | 230 | 2015 |
| Diagnostic accuracy of noninvasive fibrosis models to detect change in fibrosis stage MS Siddiqui, G Yamada, R Vuppalanchi, M Van Natta, R Loomba, C Guy, ... Clinical gastroenterology and hepatology 17 (9), 1877-1885. e5, 2019 | 208 | 2019 |
| Covert hepatic encephalopathy is independently associated with poor survival and increased risk of hospitalization KR Patidar, LR Thacker, JB Wade, RK Sterling, AJ Sanyal, MS Siddiqui, ... Official journal of the American College of Gastroenterology| ACG 109 (11 …, 2014 | 198 | 2014 |
| Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis J Quek, KE Chan, ZY Wong, C Tan, B Tan, WH Lim, DJH Tan, ASP Tang, ... The lancet Gastroenterology & hepatology 8 (1), 20-30, 2023 | 195 | 2023 |
| Validation of EncephalApp, smartphone-based Stroop test, for the diagnosis of covert hepatic encephalopathy JS Bajaj, DM Heuman, RK Sterling, AJ Sanyal, M Siddiqui, S Matherly, ... Clinical Gastroenterology and Hepatology 13 (10), 1828-1835. e1, 2015 | 195 | 2015 |
| The global burden of metabolic disease: Data from 2000 to 2019 NWS Chew, CH Ng, DJH Tan, G Kong, C Lin, YH Chin, WH Lim, ... Cell Metabolism 35 (3), 414-428. e3, 2023 | 192 | 2023 |
| Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta … DJH Tan, CH Ng, SY Lin, XH Pan, P Tay, WH Lim, M Teng, N Syn, G Lim, ... The Lancet Oncology 23 (4), 521-530, 2022 | 163 | 2022 |
| Randomised clinical study: GR‐MD‐02, a galectin‐3 inhibitor, vs. placebo in patients having non‐alcoholic steatohepatitis with advanced fibrosis SA Harrison, SR Marri, N Chalasani, R Kohli, W Aronstein, GA Thompson, ... Alimentary Pharmacology & Therapeutics 44 (11-12), 1183-1198, 2016 | 161 | 2016 |
| Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science MS Siddiqui, SA Harrison, MF Abdelmalek, QM Anstee, P Bedossa, ... Hepatology 67 (5), 2001-2012, 2018 | 160 | 2018 |
| An observational data meta-analysis on the differences in prevalence and risk factors between MAFLD vs NAFLD GEH Lim, A Tang, CH Ng, YH Chin, WH Lim, DJH Tan, JN Yong, J Xiao, ... Clinical Gastroenterology and Hepatology 21 (3), 619-629. e7, 2023 | 144 | 2023 |
| Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension G Garcia-Tsao, J Bosch, Z Kayali, SA Harrison, MF Abdelmalek, E Lawitz, ... Journal of hepatology 72 (5), 885-895, 2020 | 141 | 2020 |
| Long-term outcomes in patients undergoing liver transplantation for nonalcoholic steatohepatitis-related cirrhosis C Bhati, MO Idowu, AJ Sanyal, M Rivera, C Driscoll, RT Stravitz, DR Kohli, ... Transplantation 101 (8), 1867-1874, 2017 | 134 | 2017 |
Arun Sanyal在 mcvh-vcu.edu 的电子邮件经过验证
